13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • ANZUP1303

    Acronym: 

    ANZUP1303

    ACTRN/NCT /ethics: 

    Scientific title: 

    Randomised phase III trial of enzalutamide in androgen deprivation therapy with radiaton therapy for high risk, clinically localised prostate cancer

    Summary of trial and patient characteristics

    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III Tumour Stream Prostate Cancer
    Age Range 18 years and older Cancer Stage In Situ
    Sex Male Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Male
    Molecular Target
    Tumour Stream Prostate Cancer
    Cancer Stage In Situ
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Randomised phase III trial of enzalutamide in androgen deprivation therapy with radiaton therapy for high risk, clinically localised prostate cancer

    Lay Summary

    Randomised phase III trial of enzalutamide in androgen deprivation therapy with radiaton therapy for high risk, clinically localised prostate cancer

    Sponsor / Cooperative group

    ENZARAD

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting